Page 6 - Carolyn Magill News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Carolyn magill. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Carolyn Magill Today - Breaking & Trending Today

Aetion Raises $110M in Series C Funding

Aetion, a NYC-based healthcare technology company, raised $110m in Series C funding.
The round was led by Warburg Pincus, with participation from B Capital and Foresite Capital and existing backers New Enterprise Associates (NEA) and Flare Capital Partners.
The company will use the new funds to extend the capabilities of its Aetion Evidence Platform®, expand its European and Asian-Pacific presence, and grow its commercial team.
Led by CEO Carolyn Magill, Aetion delivers real-world evidence for the manufacturers, purchasers, and regulators of medical treatments and technologies. The Aetion Evidence Platform® analyzes data from the real world to produce transparent, rapid, and scientifically validated answers on safety, effectiveness, and value. It informs health care’s decisions what works best, for whom, and when to guide product development, commercialization, and payment innovation. ....

Carolyn Magill , Warburg Pincus , Enterprise Associates , Foresite Capital , New Enterprise Associates , Flare Capital , Aetion Evidence Platform , கரோலின் ம்யாஜைல் , வார்பர்க் பிங்கஸ் , நிறுவன கூட்டாளிகள் , புதியது நிறுவன கூட்டாளிகள் , விரிவடைய மூலதனம் ,

Research institute taps into RWE to assess therapies

The Institute for Clinical and Economic Review will use Aetion observational real-world evidence to evaluate potential drugs from Takeda and CSL Behring.
The Institute for Clinical and Economic Review (ICER), a non-profit research institute that evaluates potential therapies and medical devices, announced it will turn to observational real-world evidence (RWE) analyzed by Aetion to update its 2018 assessments of three potential angioedema treatments. The treatments are intended for long-term prophylaxis against hereditary angioedema (HAE) attacks: Takeda’s lanadelumab (Takhzyro), and two C1 esterase inhibitors: CSL Behring’s Haegarda, and Takeda’s Cinryze).
The updated assessment is part of an ongoing research partnership between the two organizations, in line with ICER’s stated commitment to expand the use of RWE in its value assessments. According to the companies, Aetion researchers will use Optum’s de-identified Clinformatics Data ....

Carolyn Magill , Jon Campbell , Behring Haegarda , Takeda Cinryze , Institute For Clinical , Economic Review , Clinformatics Data Mart , Medicare Advantage , Aetion Evidence Platform , Preclinical Research , Clinical Development , Atient Centricity , Linical Evolution , Data Management , Real World Evidence , Real World Data , கரோலின் ம்யாஜைல் , ஜான் கேம்ப்பெல் , நிறுவனம் க்கு மருத்துவ , பொருளாதார விமர்சனம் ,

ICER to Use Aetion Observational RWE to Update Value Assessment of Treatments for Hereditary Angioedema

ICER to Use Aetion Observational RWE to Update Value Assessment of Treatments for Hereditary Angioedema
- New ICER pilot will incorporate more than 24 months of observational real-world demographic, utilization, and cost data to further clarify therapies value
- Through continued use of the Aetion Evidence Platform®, ICER advances the use of transparent, replicable real-world evidence in health technology assessment
News provided by
Share this article
ICER) today announced it is using observational real-world evidence (RWE) to update its
2018 assessment of three therapies for long-term prophylaxis against hereditary angioedema (HAE) attacks: lanadelumab (Takhzyro®, Takeda), and two C1 esterase inhibitors (Haegarda®, CSL Behring; and Cinryze®, Takeda). ....

New York , United States , Carolyn Magill , Jon Campbell , England Comparative Effectiveness Public Advisory Council , Horizon Health Services Inc , California Technology Assessment Forum , Harvard Medical School , Midwest Comparative Effectiveness Public Advisory Council , Research Protocol , Health Economics , University Of Washington , Institute For Clinical , Enterprise Associates , Economic Review , Gdata Mart , Medicare Advantage , Vice President , Aetion Evidence Platform , Modeling Analysis , New York City , New Enterprise Associates , Flare Capital Partners , Town Hall Ventures , Mckesson Ventures , Sanofi Ventures ,

First RCT-DUPLICATE Findings Published in Circulation

Share this article
Share this article
NEW YORK, Dec. 17, 2020 /PRNewswire/ Real-world evidence (RWE) studies can offer comparable insights to randomized controlled trials (RCTs), particularly when the intent is to compare clinically meaningful treatment scenarios using rigorous study design and fit-for-purpose data, according to results from the RCT-DUPLICATE project published today in
Circulation. Researchers from Brigham and Women s Hospital (BWH) and Harvard Medical School, in close collaboration with the U.S. Food and Drug Administration (FDA) and Aetion, reported the findings from 10 RWE studies designed to emulate RCTs for cardiovascular outcomes of antidiabetic or antiplatelet medications.
Nine of the 10 RWE studies achieved at least two of three agreement metrics that researchers set at the outset. For each of these nine studies, the difference in results between the RWE and RCT was not statistically significant. Eight of the nine RWE findings achieved ....

New York , United States , Carolyn Magill , Jessica Franklin , World Evidence Program , Horizon Health Services Inc , Drug Administration , Harvard Medical School , Udall Foundation , Agency Real , Enterprise Associates , Office Of Medical Policy , Friends Of Cancer Research , Century Cures Act , Drug Evaluation , Medical Policy , Real World Evidence , Aetion Evidence Platform , Reagan Udall Foundation , Cancer Research , New York City , New Enterprise Associates , Flare Capital Partners , Town Hall Ventures , Mckesson Ventures , Sanofi Ventures ,